{"Symbol": "ARTL", "AssetType": "Common Stock", "Name": "Artelo Biosciences Inc", "Description": "Artelo Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. The company is headquartered in La Jolla, California.", "CIK": "1621221", "Exchange": "NASDAQ", "Currency": "USD", "Country": "USA", "Sector": "HEALTHCARE", "Industry": "BIOTECHNOLOGY", "Address": "505 LOMAS SANTA FE, SOLANA BEACH, CA, UNITED STATES, 92075", "OfficialSite": "https://www.artelobio.com", "FiscalYearEnd": "December", "LatestQuarter": "2025-09-30", "MarketCapitalization": "3512600", "EBITDA": "-7440756", "PERatio": "None", "PEGRatio": "None", "BookValue": "-0.407", "DividendPerShare": "None", "DividendYield": "None", "EPS": "-19.5", "RevenuePerShareTTM": "0", "ProfitMargin": "0", "OperatingMarginTTM": "0", "ReturnOnAssetsTTM": "-1.363", "ReturnOnEquityTTM": "-4.361", "RevenueTTM": "0", "GrossProfitTTM": "0", "DilutedEPSTTM": "-19.5", "QuarterlyEarningsGrowthYOY": "0", "QuarterlyRevenueGrowthYOY": "0", "AnalystTargetPrice": "18", "AnalystRatingStrongBuy": "-", "AnalystRatingBuy": "-", "AnalystRatingHold": "-", "AnalystRatingSell": "-", "AnalystRatingStrongSell": "-", "TrailingPE": "-", "ForwardPE": "-", "PriceToSalesRatioTTM": "-", "PriceToBookRatio": "0.498", "EVToRevenue": "-", "EVToEBITDA": "1.215", "Beta": "1.024", "52WeekHigh": "28.6", "52WeekLow": "1.15", "50DayMovingAverage": "3.529", "200DayMovingAverage": "6.84", "SharesOutstanding": "2018700", "SharesFloat": "2009200", "PercentInsiders": "0.473", "PercentInstitutions": "1.637", "DividendDate": "2019-06-21", "ExDividendDate": "None"}